Guggenheim lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $12 from $18 and keeps a Buy rating on the shares. The firm, which believes the company’s cost-cutting and focus on achieving profitability with the current balance sheet is “the right approach taken by the new CEO and should be welcomed by the Street,” has updated its model to reflect a lower growth ramp and peak sales estimate for Voquezna.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals price target lowered to $20 from $28 at H.C. Wainwright
- Phathom Pharmaceuticals Reports Q1 2025 Financial Results
- Phathom Pharmaceuticals Eyes Profitability Amid Growth
- Positive Outlook for Phathom Pharmaceuticals Amid Cost-Cutting and Regulatory Catalysts
- Phathom Pharmaceuticals reports Q1 EPS ($1.07), consensus ($1.07)